Rectal Cancer Clinical Trials

735 recruitingLast updated: June 17, 2026

There are 735 actively recruiting rectal cancer clinical trials across 55 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Guangzhou, Guangdong, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Rectal Cancer Trials at a Glance

735 actively recruiting trials for rectal cancer are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Phase 2 with 270 trials, with the heaviest enrollment activity in Houston, Guangzhou, and New York. Lead sponsors running rectal cancer studies include Fudan University, Sun Yat-sen University, and City of Hope Medical Center.

Browse rectal cancer trials by phase

Treatments under study

About Rectal Cancer Clinical Trials

Looking for clinical trials for Rectal Cancer? There are currently 198 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rectal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rectal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 735 trials

Recruiting
Phase 3

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.1,020 enrolled8 locationsNCT07549412
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Not Applicable

Family Communications After Genetic Testing

Stage IV Colorectal Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology4,186 enrolled242 locationsNCT07143487
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
AbbVie390 enrolled51 locationsNCT06820463
Recruiting
Phase 3

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Unresectable Metastatic Colorectal Cancer
University Hospital, Tours244 enrolled4 locationsNCT06642844
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 2

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Colo-rectal Cancer
NSABP Foundation Inc79 enrolled9 locationsNCT07058012
Recruiting
Not Applicable

The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

Rectal Cancer
Weill Medical College of Cornell University25 enrolled5 locationsNCT05943210
Recruiting
Phase 2

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Colorectal Cancer (CRC)
Tao Zhang48 enrolled1 locationNCT07644286
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 2

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Colorectal, CancerColon CancerRectal Cancer+1 more
SCRI Development Innovations, LLC60 enrolled14 locationsNCT07011576
Recruiting
Phase 1

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled7 locationsNCT06459869
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Advanced Microsatellite Stable Colorectal Cancer
Gilead Sciences170 enrolled5 locationsNCT07527858
Recruiting
Phase 2

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Colon CancerdMMR Colorectal Cancer
University of Iowa25 enrolled2 locationsNCT05239546
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Not Applicable

Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision

Rectal Cancer PatientsRobotic Assisted Intervention
Sun Yat-sen University216 enrolled1 locationNCT07651553
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814